10-Q: Health Catalyst Reports Q1 2026 Results, Faces Revenue Decline

Health Catalyst Inc. reported a significant increase in net loss for Q1 2026, primarily due to a $95.5 million goodwill impairment, while total revenue decreased year-over-year.

Summary

• Health Catalyst, Inc. reported total revenue of $70.8 million for the three months ended March 31, 2026, a decrease of 11% from $79.4 million in the same period of 2025.
• Technology revenue was $49.5 million, down 4% year-over-year, while professional services revenue decreased by 24% to $21.3 million.
• The company incurred a net loss of $111.0 million for Q1 2026, a substantial increase from the $23.7 million net loss in Q1 2025, largely driven by a $95.5 million goodwill impairment charge.
• Adjusted EBITDA improved to $9.1 million from $6.3 million in the prior year's quarter, indicating operational improvements outside of GAAP measures.
• The company is undergoing restructuring initiatives, including Project Nexus, which aims to transform its operating model and align resources, with expected charges of at least $4.0 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss, revenue decline, and substantial goodwill impairment, despite some positive non-GAAP metric improvements.

Positives

• Adjusted EBITDA improved to $9.1 million from $6.3 million in the prior year's quarter.
• Adjusted Gross Margin for Technology increased to 65% from 67% in the prior year, and for Professional Services increased to 19% from 16%.
• Total Adjusted Gross Margin increased to 51% from 49% in the prior year.
• The company has $24.8 million remaining authorization under its share repurchase plan.
• Cash and cash equivalents, and short-term investments totaled $108.8 million as of March 31, 2026.

Negatives

• Total revenue decreased by 11% to $70.8 million in Q1 2026 compared to $79.4 million in Q1 2025.
• Technology revenue decreased by 4% to $49.5 million, primarily due to client churn and down-selling related to DOS to Ignite migrations.
• Professional services revenue decreased by 24% to $21.3 million, attributed to exiting lower-margin TEMS arrangements and churn in FTE-based arrangements.
• Net loss widened significantly to $111.0 million in Q1 2026 from $23.7 million in Q1 2025.
• A substantial goodwill impairment charge of $95.5 million was recorded in Q1 2026.
• Technology gross margin decreased from 51% to 49% year-over-year, and Adjusted Technology Gross Margin decreased from 67% to 65%.

Risks

• Continued adverse impact from macroeconomic challenges including high inflation, high interest rates, uncertainty with tariffs, cuts in Medicaid and research funding, regional or global conflicts, and the tight labor market.
• Potential for further client churn and down-selling, particularly related to the migration from DOS to Health Catalyst Ignite.
• Long and unpredictable sales cycles for new platform clients.
• Dependence on third-party providers for computing infrastructure, such as Microsoft Azure, with potential for service disruptions.
• Risk of failure to innovate and provide useful services, leading to loss of competitiveness.
• Potential for claims against the company if its Solution is associated with faulty clinical decisions or treatment.
• Increasing reliance on AI and machine learning technologies, which carries risks related to development, deployment, regulatory uncertainties, and potential third-party claims.
• Intense competition in the healthcare solutions market from established players and new entrants.
• Potential for cybersecurity threats, cyberattacks, or deficiencies in cybersecurity measures.
• Failure to comply with data protection, privacy, and security laws, including HIPAA and state-specific regulations.
• The company's significant net losses and accumulated deficit, raising concerns about future profitability and ability to generate sufficient cash flow.
• The Credit Agreement contains covenants that restrict the company's ability to take certain actions and may limit its ability to operate or grow.

Future Outlook

The company expects technology gross margin and Adjusted Technology Gross Margin to continue to fluctuate and potentially decline in the near term due to ongoing transition costs for DOS clients to Health Catalyst Ignite and Ninja Universe deployment costs. However, they anticipate long-term improvement in technology and professional services gross margins. The company expects near-term revenue growth to be negatively impacted by policy developments around Medicaid and research funding reductions, as well as a reduction in TEMS revenue and technology revenue related to DOS to Ignite migrations. The company expects Project Nexus to increase R&D expenses in Q2 2026 due to severance costs, but anticipates future reductions in ongoing R&D expenses due to headcount reductions.

Management Comments

• We believe healthcare is at an inflection point, due to financial pressure on health systems, including eroding margins, shifting payor mix, and rising labor costs.
• Moving forward our focus is building a technology business that wins in the market, operating with efficiency and discipline, and investing in our AI-enabled intelligence that differentiates our solutions.
• We are focused on margin expansion as part of our transformation to streamline operations and optimize our cost structure.
• We believe that our ability to expand within our client base will enable us to drive growth.

Industry Context

StockSavvy.ai notes that Health Catalyst's Q1 2026 results reflect ongoing challenges within the healthcare IT sector, particularly concerning client migration strategies and macroeconomic pressures impacting healthcare providers' spending. The significant goodwill impairment highlights the market's re-evaluation of growth expectations for companies in this space.

Comparison to Industry Standards

• The company's technology gross margin of 49% (Adjusted 65%) is below the typical high-margin software-as-a-service (SaaS) benchmarks, which often exceed 70-80%.
• The decline in professional services revenue and margin is a common trend for companies shifting focus to recurring software revenue, though the company's professional services margin improvement is a positive sign.
• The significant goodwill impairment of $95.5 million is a substantial write-down, indicating that the market valuation of acquired assets and future cash flows has deteriorated significantly, a trend seen in some other technology companies facing market corrections or integration challenges.

Management Changes

Legal Proceedings

• No specific legal proceedings are detailed as having a material adverse effect on the business, financial condition, or cash flows.

Related Party Transactions

• Revenue recognized from a client, Carle Health, where a member of its executive leadership team serves on Health Catalyst's board of directors, was $4.3 million for Q1 2026 and $4.4 million for Q1 2025.
• Receivables from Carle Health were $1.3 million as of March 31, 2026, and $1.7 million as of December 31, 2025.
• Deferred revenue with Carle Health was $3.3 million as of March 31, 2026, and $0.2 million as of December 31, 2025.

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances and potential volatility in stock price due to the company's financial performance and market conditions.
• Employees may be impacted by restructuring initiatives like Project Nexus, which involves workforce reductions.
• Clients may experience impacts from the DOS to Ignite migration, including potential service disruptions or changes in offerings.
• Creditors are subject to the company's debt obligations and covenants outlined in the Credit Agreement.

Next Steps

• Continue to manage the business with a focus on operating efficiency.
• Invest in AI-enabled intelligence to differentiate solutions.
• Strengthen and simplify the commercial engine to drive technology ARR bookings.
• Improve client retention through more predictable migrations and clearer client value realization.
• Increase efficiency and reduce time to value by eliminating operational complexity and scaling work through automation and global resources.
• Leverage intellectual property by combining data foundation with expertise, content, and AI-enabled solutions.
• Continue to refine the strategic operating plan, including Project Nexus.

Key Dates

Recommendation

While the company shows some positive trends in non-GAAP metrics and has a clear strategy for transformation, the significant revenue decline, widening net loss, and substantial goodwill impairment indicate considerable headwinds. The ongoing restructuring and migration challenges, coupled with macroeconomic pressures, warrant a cautious approach. Investors should monitor the execution of Project Nexus and the impact of client migration on revenue and margins before considering a more aggressive stance.

Keywords

Health Catalyst, HCAT, Form 10-Q, Quarterly Report, Healthcare Analytics, Data Platform, Financial Results, Goodwill Impairment, Restructuring, Project Nexus, DOS to Ignite Migration